Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL327550 | 0.88 | — | — | |
| SCHEMBL27964995 | 0.82 | ALDH1A1 (0.55) | ALDH1A1CYP3A4ALOX15TDP1USP2 | |
| SCHEMBL7094868 | 0.80 | ALDH1A1 (0.67) | ALDH1A1CYP3A4ALOX15TDP1USP2 | |
| SCHEMBL11060991 | 0.80 | ALDH1A1 (0.61) | ALDH1A1CYP3A4ALOX15TDP1USP2 | |
| SCHEMBL20878209 | 0.80 | ALDH1A1 (0.86) | ALDH1A1CYP3A4ALOX15TDP1USP2 | |
| SCHEMBL7093157 | 0.78 | ALDH1A1 (0.70) | ALDH1A1CYP3A4ALOX15TDP1USP2 | |
| SCHEMBL919385 | 0.77 | — | — | |
| SCHEMBL5726618 | 0.77 | — | — | |
| SCHEMBL5547775 | 0.76 | ALDH1A1 (0.49) | ALDH1A1CYP3A4ALOX15TDP1USP2 | |
| SCHEMBL24478868 | 0.75 | ALDH1A1 (0.56) | ALDH1A1CYP3A4ALOX15TDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700658-B2 | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity | PFIZER INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090156685-A1 | (R)-CHIRAL HALOGENATED SUBSTITUTED FUSED HETEROCYCLIC AMINO COMPOUNDS USEFUL FOR INHIBITING CHOLESTEROL ESTER TRANSFER PROTEIN ACTIVITY | PFIZER INC | 2009-06-18 | — | — | US | disclosed |
| EP-1115693-B9 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO CO (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070219274-A1 | (R)-Chiral Halogenated Substituted Fused Heterocyclic Amino Compounds Useful for Inhibiting Cholesterol Ester Transfer Protein Activity | PFIZER INC | 2007-09-20 | — | — | US | disclosed |
| US-7253211-B2 | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity | PFIZER INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1115693-B1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO CO (US) | 2007-05-02 | — | — | EP | disclosed |
| US-7122536-B2 | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity | PFIZER INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20060229304-A1 | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity | PFIZER INC | 2006-10-12 | — | — | US | disclosed |
| US-7119094-B1 | Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade | WARNER-LAMBERT COMPANY (US) | 2006-10-10 | — | — | US | disclosed |
| US-7015230-B1 | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2006-03-21 | — | — | US | disclosed |
| WO-2001005748-A1 | OLIGOMERIC AMINO ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | MONSANTO COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-2000069832-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRYMIDINONES USEFUL AS ANTICOAGULANTS | PHARMACIA CORPORATION (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000069833-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS AS ANTICOAGULATIVE AGENTS | PHARMACIA CORPORATION (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000069826-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000069834-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000063195-A1 | NOVEL HETEROCYCLIC AMINO CARBONYL DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-10-26 | — | — | WO | disclosed |
| WO-2000044731-A1 | NOVEL HYDROXYAMIDINO CARBOXYLATE DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000018723-A1 | SUBSTITUTED N-ALIPHATIC-N-AROMATIC TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
| WO-2000018724-A1 | (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219274-A1 | (R)-Chiral Halogenated Substituted Fused Heterocyclic Amino Compounds Useful for Inhibiting Cholesterol Ester Transfer Protein Activity | CETP, DBI, MTTP | ALDH1A1 3497/4885CYP3A4 1489/4885ALOX15 2746/4885 |
| US-20060229304-A1 | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity | CETP, DBI, MTTP | ALDH1A1 3497/4885CYP3A4 1489/4885ALOX15 2746/4885 |
| US-20090156685-A1 | (R)-CHIRAL HALOGENATED SUBSTITUTED FUSED HETEROCYCLIC AMINO COMPOUNDS USEFUL FOR INHIBITING CHOLESTEROL ESTER TRANSFER PROTEIN ACTIVITY | CETP, DBI, MTTP | ALDH1A1 3497/4885CYP3A4 1489/4885ALOX15 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.